Susquehanna International Group
IOVA icon

Susquehanna International Group’s Iovance Biotherapeutics IOVA Stock Holding History

Susquehanna International Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6M Buy
1,709,100
+18,000
+1% +$57.6K ﹤0.01% 3935
2025
Q4 		$4.62M Buy
1,691,100
+255,900
+18% +$592K ﹤0.01% 4151
2025
Q3 		$3.11M Buy
1,435,200
+1,056,000
+278% +$2.49M ﹤0.01% 4908
2025
Q2 		$652K Sell
379,200
-243,900
-39% -$607K ﹤0.01% 8546
2025
Q1 		$2.07M Buy
623,100
+190,500
+44% +$982K ﹤0.01% 5456
2024
Q4 		$3.2M Sell
432,600
-361,900
-46% -$3.35M ﹤0.01% 4364
2024
Q3 		$7.46M Buy
794,500
+176,200
+28% +$1.67M ﹤0.01% 3006
2024
Q2 		$4.96M Sell
618,300
-1,190,700
-66% -$12.8M ﹤0.01% 3458
2024
Q1 		$26.8M Buy
1,809,000
+801,500
+80% +$9.33M ﹤0.01% 1502
2023
Q4 		$8.19M Buy
1,007,500
+336,900
+50% +$1.76M ﹤0.01% 2919
2023
Q3 		$3.05M Buy
670,600
+358,700
+115% +$2.34M ﹤0.01% 4354
2023
Q2 		$2.2M Buy
311,900
+212,100
+213% +$1.52M ﹤0.01% 4960
2023
Q1 		$610K Buy
99,800
+35,500
+55% +$245K ﹤0.01% 8085
2022
Q4 		$411K Sell
64,300
-375,800
-85% -$2.93M ﹤0.01% 8339
2022
Q3 		$4.22M Buy
440,100
+24,500
+6% +$283K ﹤0.01% 3426
2022
Q2 		$4.59M Buy
415,600
+115,900
+39% +$1.52M ﹤0.01% 3326
2022
Q1 		$4.99M Sell
299,700
-197,600
-40% -$3.06M ﹤0.01% 3640
2021
Q4 		$9.49M Buy
497,300
+298,800
+151% +$6.58M ﹤0.01% 2798
2021
Q3 		$4.89M Sell
198,500
-42,800
-18% -$1.01M ﹤0.01% 3995
2021
Q2 		$6.28M Buy
241,300
+60,200
+33% +$1.56M ﹤0.01% 3615
2021
Q1 		$5.73M Sell
181,100
-488,000
-73% -$20.2M ﹤0.01% 3646
2020
Q4 		$31M Buy
669,100
+349,100
+109% +$13.9M 0.01% 1343
2020
Q3 		$10.5M Sell
320,000
-66,100
-17% -$2.03M ﹤0.01% 2113
2020
Q2 		$10.6M Sell
386,100
-116,100
-23% -$3.82M ﹤0.01% 2066
2020
Q1 		$15M Buy
502,200
+132,500
+36% +$3.51M ﹤0.01% 1387
2019
Q4 		$10.2M Buy
369,700
+234,400
+173% +$5.33M ﹤0.01% 2060
2019
Q3 		$2.46M Buy
135,300
+32,500
+32% +$719K ﹤0.01% 3813
2019
Q2 		$2.52M Sell
102,800
-3,800
-4% -$57.2K ﹤0.01% 3735
2019
Q1 		$1.01M Buy
106,600
+7,800
+8% +$75.8K ﹤0.01% 5024
2018
Q4 		$874K Sell
98,800
-214,700
-68% -$2.07M ﹤0.01% 4941
2018
Q3 		$3.53M Buy
313,500
+208,400
+198% +$2.96M ﹤0.01% 3140
2018
Q2 		$1.34M Sell
105,100
-59,600
-36% -$871K ﹤0.01% 4755
2018
Q1 		$2.78M Buy
164,700
+111,600
+210% +$1.69M ﹤0.01% 3373
2017
Q4 		$425K Buy
53,100
+39,600
+293% +$318K ﹤0.01% 6934
2017
Q3 		$105K Sell
13,500
-100,000
-88% -$633K ﹤0.01% 8338
2017
Q2 		$834K Buy
113,500
+14,800
+15% +$94.1K ﹤0.01% 5651
2017
Q1 		$735K Sell
98,700
-8,300
-8% -$60.8K ﹤0.01% 5762
2016
Q4 		$744K Sell
107,000
-9,700
-8% -$66.7K ﹤0.01% 6140
2016
Q3 		$960K Buy
116,700
+34,500
+42% +$292K ﹤0.01% 4883
2016
Q2 		$666K Buy
+82,200
New +$516K ﹤0.01% 5623
2016
Q1 		– Sell
-116,800
Closed -$902K – 9317
2015
Q4 		$902K Buy
116,800
+92,000
+371% +$638K ﹤0.01% 5622
2015
Q3 		$143K Buy
+24,800
New +$193K ﹤0.01% 8957

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Susquehanna International Group's IOVA Position: Q1 2026 in Review

Susquehanna International Group reduced its Iovance Biotherapeutics (IOVA) stake by 39% in Q1 2026, selling an estimated $6.24M and leaving 2,996,743 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3040.

Susquehanna International Group first reported a position in IOVA in Q1 2015 and has held it in 35 quarters since. The position peaked at $26.9M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Susquehanna International Group held 2,996,743 shares of Iovance Biotherapeutics worth $10.5M as of Q1 2026.
  • Susquehanna International Group sold 1,951,871 Iovance Biotherapeutics shares in Q1 2026, an estimated $6.24M.
  • Iovance Biotherapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3040 holding.
  • Susquehanna International Group first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 35 quarters since.
  • Susquehanna International Group's Iovance Biotherapeutics position peaked at $26.9M in Q1 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.